Regeneron Pharmaceuticals Inc. buy Kilianhammernick
Start price
13.10.21
/
50%
€470.00
Target price
13.10.22
-
Performance (%)
24.89%
End price
13.03.22
€587.00
Summary
This prediction ended on 13.03.22 with a price of €587.00. The prediction had a final performance of 24.89%. Kilianhammernick has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -1.035% | -1.035% | 13.907% |
| iShares Core DAX® | -0.870% | -1.700% | 10.560% |
| iShares Nasdaq 100 | -5.561% | -3.604% | 34.335% |
| iShares Nikkei 225® | -6.138% | -7.732% | 16.215% |
| iShares S&P 500 | -3.141% | -2.011% | 24.534% |
Comments by Kilianhammernick for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Kilianhammernick hat das Wertpapier Regeneron Pharmaceuticals Inc. in seinem Wikifolio Alternative Invest gekauft.